Overview

CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome

Status:
Active, not recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

This pilot study is designed to evaluate outcomes with the combination of CPX-351 salvage therapy and haplo-cord graft stem cell transplantation for subjects with relapsed or refractory AML or myelodysplastic syndrome.

Phase:

Phase 1

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborator:

Jazz Pharmaceuticals

Treatments:

Cytarabine
Daunorubicin
Fludarabine
Melphalan
Thymoglobulin